Treatments no longer in development for rheumatoid arthritis.
作者信息
Keystone E
机构信息
The Centre for Advanced Therapeutics, Mount Sinai Hospital and University of Toronto, Canada.
出版信息
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii43-5. doi: 10.1136/ard.61.suppl_2.ii43.
Abstract
摘要
相似文献
1
Treatments no longer in development for rheumatoid arthritis.
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii43-5. doi: 10.1136/ard.61.suppl_2.ii43.
2
[Cytokines and anti-cytokine therapy in rheumatoid arthritis].
Internist (Berl). 2001 Jan;42(1):55-6, 59-63. doi: 10.1007/s001080050724.
3
[New treatments for rheumatoid arthritis].
Soins. 2004 Sep(688):37-8.
4
Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.
BMJ. 2002 Feb 9;324(7333):312-3. doi: 10.1136/bmj.324.7333.312.
5
When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
Ann Rheum Dis. 2008 Nov;67(11):1497-8. doi: 10.1136/ard.2008.098111.
6
Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment.
Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I61-4. doi: 10.1136/ard.58.2008.i61.
7
Tumor necrosis factor inhibitors for rheumatoid arthritis.
N Engl J Med. 2006 Nov 9;355(19):2046-7; author reply 2048. doi: 10.1056/NEJMc062500.
8
Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis.
Z Rheumatol. 1998 Feb;57(1):41-5. doi: 10.1007/s003930050058.
9
[Experimental therapy of rheumatoid arthritis with antibodies to tumor necrosis factor].
Z Rheumatol. 1998 Oct;57(5):298-301. doi: 10.1007/s003930050115.
10
Adalimumab for rheumatoid arthritis.
Expert Opin Biol Ther. 2006 Dec;6(12):1349-60. doi: 10.1517/14712598.6.12.1349.
引用本文的文献
1
A large-scale Boolean model of the rheumatoid arthritis fibroblast-like synoviocytes predicts drug synergies in the arthritic joint.
NPJ Syst Biol Appl. 2023 Jul 15;9(1):33. doi: 10.1038/s41540-023-00294-5.
2
Self-reactive T cells induce and perpetuate chronic relapsing arthritis.
Arthritis Res Ther. 2020 Apr 28;22(1):95. doi: 10.1186/s13075-020-2104-7.
3
MMPs and ADAMs in neurological infectious diseases and multiple sclerosis.
Cell Mol Life Sci. 2019 Aug;76(16):3097-3116. doi: 10.1007/s00018-019-03174-6. Epub 2019 Jun 6.
4
Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.
Int J Mol Sci. 2017 Apr 25;18(5):905. doi: 10.3390/ijms18050905.
5
Of mice and men: how animal models advance our understanding of T-cell function in RA.
Nat Rev Rheumatol. 2014 Mar;10(3):160-70. doi: 10.1038/nrrheum.2013.205. Epub 2014 Jan 7.
6
The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
Nat Rev Rheumatol. 2012 Mar 13;8(4):235-43. doi: 10.1038/nrrheum.2012.23.
7
Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis.
J Clin Immunol. 2012 Aug;32(4):709-20. doi: 10.1007/s10875-012-9674-3. Epub 2012 Feb 25.
8
The Development of Novel Therapies for Rheumatoid Arthritis.
Expert Opin Ther Pat. 2008 Jul;18(7):723-738. doi: 10.1517/13543776.18.7.723.
9
Rosmarinic acid induces apoptosis of activated T cells from rheumatoid arthritis patients via mitochondrial pathway.
J Clin Immunol. 2007 Jan;27(1):36-45. doi: 10.1007/s10875-006-9057-8. Epub 2006 Dec 29.
本文引用的文献
1
2
Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis.
Arthritis Rheum. 2001 Jan;44(1):3-12. doi: 10.1002/1529-0131(200101)44:1<3::AID-ANR2>3.0.CO;2-U.
3
Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
Pharmacol Ther. 1997;75(1):69-75. doi: 10.1016/s0163-7258(97)00023-5.
4
Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo.
Br J Pharmacol. 1997 Jun;121(3):540-6. doi: 10.1038/sj.bjp.0701150.
5
Lambda light chain deposition disease presenting as sicca syndrome.
Arthritis Rheum. 1997 Mar;40(3):587-8. doi: 10.1002/art.1780400330.
6
Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience.
Arthritis Rheum. 1996 Nov;39(11):1773-80. doi: 10.1002/art.1780391102.
7
A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.
Arthritis Rheum. 1996 Jul;39(7):1102-8. doi: 10.1002/art.1780390705.
8
Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens.
Arthritis Rheum. 1996 Jan;39(1):52-6. doi: 10.1002/art.1780390107.
9
In vivo T cell depletion in rheumatoid arthritis is associated with increased in vitro IgM-rheumatoid factor synthesis.
Clin Immunol Immunopathol. 1993 May;67(2):124-9. doi: 10.1006/clin.1993.1054.
10
A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.
Arthritis Rheum. 1995 Aug;38(8):1097-106. doi: 10.1002/art.1780380812.
Zotero 插件